Georgia Medicare Prostate Cancer Screening (2026) Guide

Medicare covers a prostate cancer screening every year for men over 50, and the test most doctors rely on, the prostate-specific antigen (PSA) blood test, costs you nothing. The surprise is the other half of the benefit. The screening digital rectal exam (DRE) is not free: you pay the Part B deductible and then 20% of the approved amount for it.1 This guide explains what Georgia Medicare prostate cancer screening covers, what each test costs, who should actually get screened, and how Georgia Medicaid can pick up the digital rectal exam cost if you have both programs.

What Georgia Medicare Prostate Cancer Screening Covers

Georgia Medicare prostate cancer screening is a Part B preventive benefit for men who have reached age 50. Medicare covers two tests once every 12 months: the prostate-specific antigen (PSA) blood test and the screening digital rectal examination (DRE).1

The PSA blood test measures the level of prostate-specific antigen, a protein made by the prostate, in a small sample of blood. A higher level can point to prostate cancer, but it can also rise from a non-cancerous enlarged prostate, an infection, or even a recent exam, so the result is a starting point for discussion rather than a diagnosis.

The digital rectal examination (DRE) is a brief physical check in which a clinician feels the prostate through the rectal wall for lumps, hard spots, or changes in size. It takes less than a minute and needs no special equipment.

The benefit itself is set by federal law: Social Security Act Section 1861(oo) and its implementing rule 42 CFR 410.39, which define the two covered tests and limit payment to men over 50. On a Medicare claim, the DRE is billed as HCPCS code G0102 and the PSA as G0103.

How Much Does Prostate Cancer Screening Cost in Georgia?

This is the part that trips people up, and it is the single most common error you will read online: prostate cancer screening is not simply "free."

The PSA blood test is $0. You pay nothing for the test itself. If your provider does not accept Medicare assignment, you may owe an additional fee for the doctor's services, but not for the test.1

The screening DRE is not $0. After you meet the annual Part B deductible, which is $283 in 2026, you pay 20% of the Medicare-approved amount for the exam and the doctor's related services.1,2 Why the difference? Most Medicare cancer screenings, such as mammograms and colorectal screening, are $0 because the United States Preventive Services Task Force (USPSTF) grades them A or B, and an Affordable Care Act rule waives cost-sharing for A and B services. The USPSTF grades PSA-based prostate screening a C for men 55 to 69 and a D for men 70 and older, and neither grade qualifies for that waiver.1 The PSA test lands at $0 separately, because it is paid under Medicare's clinical laboratory rules, which carry no cost-sharing.

Who Qualifies, and How Often Medicare Pays

Any man with Medicare Part B qualifies for prostate cancer screening the year he turns 50; coverage is not available at age 50 or younger.1 Most men reach this benefit at 65 when they enroll in Medicare, but men who qualify earlier through disability or End-Stage Renal Disease are eligible at 50 as well.

Medicare pays for each test once every 12 months. In practice, the rule in 42 CFR 410.39 allows the next covered screening after 11 full months have passed since the last one, so an exam done in June is covered again the following June.1

Should You Get Screened? USPSTF Shared Decision-Making

Being covered is not the same as being advised to screen. The USPSTF recommends that men aged 55 to 69 make an individual decision about PSA screening after talking through the benefits and harms with their clinician (Grade C), and it recommends against routine PSA screening for men 70 and older (Grade D).1

The reason for the caution is that screening can find slow-growing cancers that would never have caused harm, and treating them can lead to lasting side effects such as incontinence and erectile dysfunction. Screening can also find aggressive cancers early, when treatment works best. A good conversation weighs your age, overall health, family history, and how you feel about those trade-offs. Many men with a low-risk cancer now choose active surveillance, close monitoring instead of immediate treatment, which avoids much of that harm.

Higher-Risk Men: African American and Family History

Some men carry a higher baseline risk, and that changes the conversation. The National Cancer Institute's SEER program puts numbers on it: the age-adjusted rate of new prostate cancer cases is 200.1 per 100,000 men per year among Non-Hispanic Black men versus 122.2 among Non-Hispanic White men (SEER 21, 2019-2023), and the prostate cancer death rate is 36.2 versus 18.1 per 100,000 men per year (U.S. mortality, 2020-2024). The CDC states it plainly: African American men are more likely to get prostate cancer than other men, and are more than twice as likely to die from it.4 Men with a father or brother diagnosed with prostate cancer are also at elevated risk. Georgia's large African American population means this discussion matters here more than in many states.

For higher-risk men, leading clinical groups such as the American Cancer Society and the American Urological Association suggest starting the screening conversation earlier, around age 45, even though Medicare coverage begins at 50. The practical takeaway is not that a higher-risk man must screen, but that he deserves a deliberate, informed discussion rather than a skipped one.

What Happens If Your PSA or Exam Is Abnormal

An abnormal result is not a cancer diagnosis. A raised PSA or a lump felt on the DRE usually leads to a repeat PSA, a referral to a urologist, and often a prostate MRI before any decision about a biopsy. This modern step, an MRI before biopsy, spares many men from a biopsy they do not need.

One thing about cost: the $0 covers screening only. Once testing becomes diagnostic, the follow-up PSA is still paid under the laboratory rules, but the urology visit, the MRI, and any biopsy carry the standard Part B deductible and 20% coinsurance.1 Your doctor or a counselor can help you understand those costs before you commit.

If You Have Both Medicare and Medicaid in Georgia

This is where a Georgia beneficiary's situation can differ sharply from the general rule. If you have both Medicare and Georgia Medicaid, or you qualify for the Qualified Medicare Beneficiary (QMB) program, Georgia Medicaid pays your Medicare Part B premiums, deductibles, and coinsurance. For 2026, a single Georgian with monthly income up to $1,350 and countable assets up to $9,950 can qualify as a QMB.3 Those are the federal standards rather than absolute cutoffs, because states can effectively raise both by disregarding certain income and resources, so someone a little over them should still apply.2

QMB is one of Georgia's Medicare Savings Programs. For you, that means the digital rectal exam's deductible and 20% coinsurance are covered, so both prostate screening tests effectively cost $0.3,1 You apply for QMB through the Georgia Division of Family and Children Services within the Georgia Department of Community Health, by calling 1-877-423-4746 or applying at Georgia Gateway.3,5

How to Get Prostate Cancer Screening in Georgia

Where to Get Help With Georgia Medicare Prostate Cancer Screening

For free, unbiased help understanding what your screening will cost, contact GeorgiaCares SHIP, Georgia's State Health Insurance Assistance Program.6 The resources below can help with coverage questions, applying for cost-sharing help, and prostate cancer support.

Learn More

Find personalized help understanding your Medicare prostate cancer screening coverage in Georgia at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.